, Volume 169, Issue 2, pp 115–134 | Cite as

Cannabinoids: reward, dependence, and underlying neurochemical mechanisms—a review of recent preclinical data



Background and rationale

Starting with the discovery of an endogenous brain cannabinoid system with specific receptors and endogenous ligands, research in the cannabinoid field has accelerated dramatically over the last 15 years. Cannabis is the most used illicit psychotropic substance in the world but only recently have reliable preclinical models become available for investigating the rewarding and dependence-producing actions of its psychoactive constituent, Δ9-tetrahydrocannabinol (THC).


The goal of this review is to examine the various animal models currently available that are being used to facilitate our understanding of the rewarding and dependence-producing actions of cannabinoids, which are central to their abuse liability, and of the neurochemical mechanisms that may underlie these actions of cannabinoids.

Results and conclusions

Recent demonstrations that strong and persistent intravenous self-administration behavior can be obtained in squirrel monkeys using a range of THC doses that are in agreement with the total intake and the single doses of THC normally self-administered by humans smoking marijuana cigarettes provides a reliable and direct tool for assessing the reinforcing effects of THC that are central to its abuse liability. In addition, recent demonstrations of persistent intravenous self-administration of synthetic cannabinoid CB1 receptor agonists by rats and mice and the development of genetically modified mice lacking specific cannabinoid receptors provide convenient rodent models for exploring underlying neurochemical mechanisms. Repeated demonstrations in rats that THC and synthetic CB1 agonists can induce conditioned place preferences or aversions, depending on details of dose and spacing, can reduce the threshold for intracranial self-stimulation behavior under certain conditions, and can serve as effective discriminative stimuli for operant behavior provide less direct, but more rapidly established, measures for investigating the rewarding effects of cannabinoids. Finally, there have been numerous recent reports of major functional interactions between endogenous cannabinoid, opioid, and dopaminergic neurotransmitter systems in areas such as analgesia, physical dependence and tolerance development, and drug reinforcement or reward. This provides an opportunity to search for drugs with the beneficial therapeutic effects of currently available cannabinoids or opioids but without undesirable adverse effects such as abuse liability.


THC Marijuana Drug self-administration Conditioned place preference Drug discrimination Cannabinoid dependence In vivo microdialysis Opioid-cannabinoid interactions 


  1. Abood ME, Sauss C, Fan F, Tilton CL, Martin BR (1993) Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 46:575–579CrossRefPubMedGoogle Scholar
  2. Aceto MD, Scates SM, Lowe JA, Martin BR (1995) Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 282:R1–R2Google Scholar
  3. Aceto MD, Scates SM, Lowe JA, Martin BR (1996) Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290–1295Google Scholar
  4. Aceto MD, Scates SM, Razdan RK, Martin BR (1998) Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther 287:598–605PubMedGoogle Scholar
  5. Aceto MD, Scates SM, Lowe JA, Martin BR (2001) Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55,212-2. Eur J Pharmacol 416:75–81CrossRefPubMedGoogle Scholar
  6. Acquas E, Di Chiara G (1992) Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J Neurochem 58:1620–1625PubMedGoogle Scholar
  7. Acquas E, Carboni E, Di Chiara G (1991) Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats. Eur J Pharmacol 193:133–134PubMedGoogle Scholar
  8. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L (1986) Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38:21–43PubMedGoogle Scholar
  9. Ameri A (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58:315–348Google Scholar
  10. Arnold JC, Topple AN, Hunt GE, McGregor IS (1998) Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine. Eur J Pharmacol 354:9–16PubMedGoogle Scholar
  11. Arnold JC, Hunt GE, McGregor IS (2001) Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sci 70:97–108CrossRefPubMedGoogle Scholar
  12. Balster RL, Prescott WR (1992) Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 16:55–62PubMedGoogle Scholar
  13. Balster RL, Schuster CR (1973) Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav 20:119–29PubMedGoogle Scholar
  14. Bardo MT, Bevins RA (2000) Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153:31–43Google Scholar
  15. Barrett RL, Wiley JL, Balster RL, Martin BR (1995) Pharmacological specificity of Δ9-tetrahydrocannabinol discrimination in rats. Psychopharmacology 118:419–424PubMedGoogle Scholar
  16. Bass CE, Martin BR (2000) Time course for the induction and maintenance of tolerance to delta-9-tetrahydrocannabinol in mice. Drug Alcohol Depend 60:113–119CrossRefPubMedGoogle Scholar
  17. Bergman J, Johnson GE (1985) The reinforcing properties of diazepam under several conditions in the rhesus monkeys. Psychopharmacology 86:108–113PubMedGoogle Scholar
  18. Braida D, Pozzi M, Cavallini R, Sala M (2001a) Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 104:923–926CrossRefPubMedGoogle Scholar
  19. Braida D, Pozzi M, Parolaro D, Sala M (2001b) Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol 413:227–234Google Scholar
  20. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ (1999) Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73:2447–2459CrossRefPubMedGoogle Scholar
  21. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155–163PubMedGoogle Scholar
  22. Budney AJ, Novy PL, Hughes JR (1999) Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94:1311–1322CrossRefPubMedGoogle Scholar
  23. Budney, AJ, Hughes JR, Moore BA, Novy PL (2001) Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry 58:917–924PubMedGoogle Scholar
  24. Burkey RT, Nation JR (1997) (R)-Methanandamide, but not anandamide, substitutes for Δ9-THC in a drug-discrimination procedure. Exp Clin Psychopharmacol 5:195–202Google Scholar
  25. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G (2001) Behavioural sensitization after repeated exposure to Δ9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 158:259–266CrossRefPubMedGoogle Scholar
  26. Calignano A, La Rana G, Piomelli D (2001) Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419:191–198Google Scholar
  27. Campbell UC, Carroll ME (2000) Acquisition of drug self-administration: environmental and pharmacological interventions. Exp Clin Psychopharmacol 8:312–325PubMedGoogle Scholar
  28. Carboni E, Imperato A, Perezzani L, Di Chiara G (1989) Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28:653–661PubMedGoogle Scholar
  29. Carney JM, Uwaydah IM, Balster, RL (1977) Evaluation of a suspension system for intravenous self-administration of water insoluble substances in the rhesus monkey. Pharmacol Biochem Behav 7:357–364CrossRefGoogle Scholar
  30. Carr KD (2002) Augmentation of drug reward by chronic food restriction: behavioral evidence and underlying mechanisms. Physiol Behav 76:353–364CrossRefPubMedGoogle Scholar
  31. Carriero D, Aberman J, Lin SY, Hill A, Makriyannis A, Salamone JD (1998) A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. Psychopharmacology 137:147–156Google Scholar
  32. Castaneda E, Moss DE, Oddie SD, Whishaw IQ (1991) THC does not affect striatal dopamine release: microdialysis in freely moving rats. Pharmacol Biochem Behav 40:587–591PubMedGoogle Scholar
  33. Chang JY, Sawyer SF, Lee RS, Woodward DJ (1994) Electrophysiological and pharmacological evidence for the role of the nucleus accumbens in cocaine self-administration in freely moving rats. J Neurosci 14:1224–1244PubMedGoogle Scholar
  34. Chaperon F, Soubrie P, Puech AJ, Thiebot MH (1998) Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 135:324–332Google Scholar
  35. Cheer JF, Kendall DA, Marsden CA (2000a) Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology 151:25–30Google Scholar
  36. Cheer JF, Marsden CA, Kendall DA, Mason R (2000b) Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study. Neuroscience 99:661–667CrossRefPubMedGoogle Scholar
  37. Chen J, Paredes W, Li J, Smith D, Lowinson JH, Gardner EL (1990) Δ9-Tetrahydrocannabinol produces naloxoneblockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156–162Google Scholar
  38. Chen J, Paredes W, Lowinson JH, Gardner EL (1991) Strain-specific facilitation of dopamine efflux by Δ9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci Lett 129:136–140PubMedGoogle Scholar
  39. Chen J, Marmur R, Pulles A, Paredes W, Gardner EL (1993) Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient. Brain Res 621:65–70CrossRefPubMedGoogle Scholar
  40. Childers SR, Breivogel CS (1998) Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 51:173–187PubMedGoogle Scholar
  41. Corchero J, Fuentes JA, Manzanares J (1997a) Delta 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur J Pharmacol 323:193–195Google Scholar
  42. Corchero J, Avila MA, Fuentes JA, Manzanares J (1997b) Δ9-tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci 61:39–43CrossRefPubMedGoogle Scholar
  43. Costa B, Parolaro D, Colleoni M (1996) Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. Eur J Pharmacol 313:17–24Google Scholar
  44. Costa B, Giagnoni G, Colleoni M (2000) Precipitated and spontaneous withdrawal in rats tolerant to anandamide. Psychopharmacology 149:121–128CrossRefPubMedGoogle Scholar
  45. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, Fratta W (2001) Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 118:61–65PubMedGoogle Scholar
  46. Coutts AA, Anavi-Goffer S, Ross RA, MacEwan DJ, Mackie K Pertwee RG, Irving AJ (2001) Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci 21:2425–2433PubMedGoogle Scholar
  47. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83–87PubMedGoogle Scholar
  48. Crowley TJ, Macdonald MJ, Whitmore EA, Mikulich SK (1998) Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. Drug Alcohol Depend 50:27–37CrossRefPubMedGoogle Scholar
  49. Damsma G, Day J, Fibiger HC (1989) Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol 168:363–368PubMedGoogle Scholar
  50. Da Silva GE, Morato GS, Takahashi RN (2001) Rapid tolerance to Delta(9)-tetrahydrocannabinol and cross-tolerance between ethanol and Delta(9)-tetrahydrocannabinol in mice. Eur J Pharmacol 431:201–207CrossRefPubMedGoogle Scholar
  51. De Fonseca RF, Fernandez-Ruiz JJ, Murphy LL, Cebeira M, Steger RW, Bartke A, Ramos JA (1992) Acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas. Pharmacol Biochem Behav 42:269–275CrossRefPubMedGoogle Scholar
  52. De Fonseca RF, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA (1994) Downregulation of rat brain cannabinoid binding sites after chronic delta-9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47:33–40PubMedGoogle Scholar
  53. De Fonseca RF, Carrera MRA, Navarro M, Koob GF, Weiss F (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276:2050–2054PubMedGoogle Scholar
  54. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613PubMedGoogle Scholar
  55. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949PubMedGoogle Scholar
  56. De Vries TJ, Schoffelmeer AN, Binnekade R, Mulder AH, Vanderschuren LJ (1998) Drug-induced reinstatement of heroin- and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioural sensitization. Eur J Neurosci 10:3565–3571PubMedGoogle Scholar
  57. Diana M, Melis M, Muntoni AL, Gessa GL (1998) Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 95:10269–10273PubMedGoogle Scholar
  58. Di Chiara G, Imperato A (1986) Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol, and barbiturates: studies with transcerebral dialysis in freely moving rats. Ann NY Acad Sci 473:367–381PubMedGoogle Scholar
  59. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274–5278PubMedGoogle Scholar
  60. Di Chiara G, North RA (1992) Neurobiology of opiate abuse. Trends Pharmacol Sci 13:185–193PubMedGoogle Scholar
  61. Di Chiara G, Tanda G, Bassareo V, Pontieri F, Acquas E, Fenu S, Cadoni C, Carboni E (1999) Drug addiction as a disorder of associative learning: role of nucleus accumbens shell/extended amygdala dopamine. Ann NY Acad Sci 877:461–485PubMedGoogle Scholar
  62. Di Marzo V (1999) Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci 65:645–655Google Scholar
  63. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686–691Google Scholar
  64. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M, Ramos JA, Fernandez-Ruiz JJ (2000) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem 74:1627–1635CrossRefPubMedGoogle Scholar
  65. Doty P, Dykstra LA, Picker MJ (1994) Discriminative stimulus effects of phencyclidine: pharmacologically specific interactions with delta 9- and delta 8-tetrahydrocannabinol. Drug Alcohol Depend 35:151–158PubMedGoogle Scholar
  66. Fattore L, Cossu G, Martellotta CM, Fratta W (2001) Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology 156:410–416Google Scholar
  67. Felder CC, Glass M (1998) Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 3:179–200Google Scholar
  68. French ED, Dillon K, Wu X (1997) Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8:649–652Google Scholar
  69. Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647Google Scholar
  70. Gardner EL, Parades W, Smith D, Zukin RS (1989) facilitation of brain stimulation reward by delta-9-tetrahydrocannabinol is mediated by an endogenous opioid mechanism. Adv Biosci 75:671–674Google Scholar
  71. Gardner EL, Vorel SR (1998) Cannabinoid transmission and reward related events. Neurobiol Dis 5:502–533PubMedGoogle Scholar
  72. Ghozland S, Mathews H, Simonin F, Filliol D, Kieffer BL, Maldonado R (2002) Motivational effects of cannabinoids are mediated by µ- and κ-opioid receptors. J Neurosci 22:1146–1154PubMedGoogle Scholar
  73. Gifford AN, Gardner EL, Ashby CR Jr (1997) The effect of intravenous administration of delta-9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats. Neuropsychobiology 36:96–99PubMedGoogle Scholar
  74. Gifford AN, Bruneus M, Lin S, Goutopoulos A, Makriyannis A, Volkow ND, Gatley SJ (1999) Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). Eur J Pharmacol 383:9–14CrossRefPubMedGoogle Scholar
  75. Giuffrida A, Beltramo M, Piomelli D (2001) Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 298:7–14PubMedGoogle Scholar
  76. Gold LH, Balster RL, Barrett RL, Britt DT, Martin BRA (1992) Comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. J Pharmacol Exp Ther 262:479–486PubMedGoogle Scholar
  77. Goldberg SR, Munzar P, Justinova Z, Tanda G (2001) Effect of naltrexone on intravenous self-administration of delta-9-tetrahydrocannabinol (THC) by squirrel monkeys under fixed-ratio and second-order schedules. In: Abstracts of the 2001 symposium on cannabinoids. International Cannabinoid Research Society, Burlington, p 102Google Scholar
  78. Gorriti MA, Rodriguez de Fonseca F, Navarro M, Palomo T (1999) Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365:133–142Google Scholar
  79. Greenwald MK, Stitzer ML (2000) Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 59:261–275CrossRefPubMedGoogle Scholar
  80. Griffiths RR, Roache JD, Ator NA, Lamb RJ, Lukas SE (1985) Similarities in reinforcing and discriminative stimulus effects of diazepam, triazolam, and pentobarbital in animals and humans. In: Seiden LS, Balster RL (eds) Behavioral pharmacology: the current status. Liss, New York, pp 419–432Google Scholar
  81. Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW (1997) Factors influencing marijuana self-administration by humans. Behav Pharmacol 8:101–112Google Scholar
  82. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395–404Google Scholar
  83. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662–3665CrossRefPubMedGoogle Scholar
  84. Harris RT, Waters W, McLendon D (1974) Evaluation of reinforcing capability of Δ9-tetrahydrocannabinol in monkeys. Psychopharmacologia 37:23–29PubMedGoogle Scholar
  85. Hernandez L, Hoebel BG (1988) Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life Sci 42:1705–1712PubMedGoogle Scholar
  86. Hillard CJ, Jarrahian A (2000) The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids 108:123–134Google Scholar
  87. Hine B, Friedman E, Torrelio M, Gershon S (1975) Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 187:443–445PubMedGoogle Scholar
  88. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99:8400–8405CrossRefPubMedGoogle Scholar
  89. Hutcheson DM, Tzavara ET Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R (1998) Behavioral and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125:1567–1577PubMedGoogle Scholar
  90. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96:14136–14141CrossRefPubMedGoogle Scholar
  91. Järbe TU, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A (1998) Δ9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology 140:519–522Google Scholar
  92. Järbe TU, Lamb RJ, Lin S, Makriyannis A (2000) Delta 9-THC training dose as a determinant for (R)-methanandamide generalization in rats: a systematic replication. Behav Pharmacol 11:81–86PubMedGoogle Scholar
  93. Järbe TU, Lamb RJ, Lin S, Makriyannis A (2001) (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology 156:369–380Google Scholar
  94. Johnson SW, North RA (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483–488PubMedGoogle Scholar
  95. Justinova Z, Tanda G, Redhi GH, Goldberg SR (2003) Self-administration of Δ9–tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology DOI 10.1007/s00213-003-1484-0Google Scholar
  96. Kalivas PW, Duffy P (1990) Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse 5:48–58PubMedGoogle Scholar
  97. Kato S, Wakasa Y, Yanagita T (1987) Relationship between minimum reinforcing doses and injection speed in cocaine and pentobarbital self-administration in crab-eating monkeys. Pharmacol Biochem Behav 28:407–10Google Scholar
  98. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, Rana GL, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76–81CrossRefPubMedGoogle Scholar
  99. Katz JL, Goldberg SR (1988) Preclinical assessment of abuse liability of drugs. Agents Actions 23:18–26Google Scholar
  100. Kaymakcalan S (1972) Physiology and psychological dependence on THC in rhesus monkeys. In: Paton WDM, Crown J (eds) Cannabis and its derivatives. Oxford University Press, London, pp 142–149Google Scholar
  101. Kaymakcalan S (1973) Tolerance to and dependence on cannabis. Bull Narc 25:39–47Google Scholar
  102. Kaymakcalan S, Ayhan IH, Tulunay FC (1977) Naloxone-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats. Psychopharmacology 55:243–249PubMedGoogle Scholar
  103. Kirk JM, De Wit H (1999) Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol Biochem Behav 63:137–142PubMedGoogle Scholar
  104. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177–184PubMedGoogle Scholar
  105. Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58PubMedGoogle Scholar
  106. Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward and allostasis. Neuropsychopharmocology 24:97–129CrossRefGoogle Scholar
  107. Kreek MJ, Koob GF (1998) Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51:23–47Google Scholar
  108. Kuczenski R, Segal DS, Aizenstein ML (1991) Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J Neurosci 11:2703–2712PubMedGoogle Scholar
  109. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1–2PubMedGoogle Scholar
  110. Lamarque S, Taghzouti K, Simon H (2001) Chronic treatment with delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 41:118–129Google Scholar
  111. Lambert DM, Di Marzo V (1999) The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 6:757–773Google Scholar
  112. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401–404PubMedGoogle Scholar
  113. Leite JR, Carlini EA (1974) Failure to obtain ''cannabis directed behavior'' and abstinence syndrome in rats chronically treated with cannabis sativa extracts. Psychopharmacologia 36:133–145Google Scholar
  114. Lepore M, Vorel SR, Lowinson J, Gardner EL (1995) Conditioned place preference induced by Δ9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci 56:2073–2080PubMedGoogle Scholar
  115. Lepore M, Liu X, Savage V, Matalon D, Gardner EL (1996) Genetic differences in Δ9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sci (Pharmacol Lett) 58:PL365–PL372Google Scholar
  116. Leuschner JT, Wing DR, Harvey DJ, Brent GA, Dempsey CE, Watts A, Paton WD (1984) The partitioning of delta 1-tetrahydrocannabinol into erythrocyte membranes in vivo and its effect on membrane fluidity. Experientia 40:866–868PubMedGoogle Scholar
  117. Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H (1981) Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 74:208–212PubMedGoogle Scholar
  118. Mailleux P, Vanderhaeghen JJ (1992) Distribution of the neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48:655–688PubMedGoogle Scholar
  119. Maldonado R (2002) Study of cannabinoid dependence in animals. Pharmacol Ther 95:153–164CrossRefPubMedGoogle Scholar
  120. Maldonado R, Rodriguez de Fonseca F (2002) Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 22:3326–3331PubMedGoogle Scholar
  121. Mallet PE, Beninger RJ (1998) Delta 9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci 62:2431–2439Google Scholar
  122. Mansbach RS, Nicholson KL, Martin BR, Balster RL (1994) Failure of Δ9-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behav Pharmacol 5:219–225Google Scholar
  123. Mansbach RS, Rovetti CC, Winston EN, Lowe JA III (1996) Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology 124:315–322Google Scholar
  124. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11:308–314PubMedGoogle Scholar
  125. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA (1998) Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Mol Brain Res 55:126–132PubMedGoogle Scholar
  126. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA (1999) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20:287–94PubMedGoogle Scholar
  127. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W (1998) Self-administration of the cannabinoid receptor agonist WIN 55,212–2 in drug-naive mice. Neuroscience 85:327–330Google Scholar
  128. Martin BR (2002) Identification of the endogenous cannabinoid system through integrative pharmacological approaches. J Pharmacol Exp Ther 301:790–796Google Scholar
  129. Martin BR, Lichtman AH (1998) Cannabinoid transmission and pain perception. Neurobiol Dis 5:447–461CrossRefPubMedGoogle Scholar
  130. Martin BR, Mechoulam R, Razdan RK (1999) Discovery and characterization of endogenous cannabinoids. Life Sci 65:573–595CrossRefGoogle Scholar
  131. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2000) Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 12:4038–4046PubMedGoogle Scholar
  132. Mascia MS, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A, Fratta W (1999) Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. Eur J Pharmacol 383:R1–R2PubMedGoogle Scholar
  133. Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, Roques BP, Noble F (2001) Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 132:1809–1816PubMedGoogle Scholar
  134. Massi P, Sacerdote P, Ponti W, Fuzio D, Manfredi B, Vigano D, Rubino T, Bardotti M, Parolaro D (1998) Immune function alterations in mice tolerant to delta9-tetrahydrocannabinol: functional and biochemical parameters. J Neuroimmunol 92:60–66Google Scholar
  135. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564PubMedGoogle Scholar
  136. McGregor IS, Issakidis CN, Prior G (1996) Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol Biochem Behav 53:657–664PubMedGoogle Scholar
  137. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83–90PubMedGoogle Scholar
  138. Merlo Pich E, Lorang M, Yeganeh M, de Fonseca FR, Raber J, Koob GF, Weiss F (1995) Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15:5439–5447PubMedGoogle Scholar
  139. Mokler DJ, Nelson BD, Harris LS, Rosecrans JA (1986) The role of benzodiazepine receptors in the discriminative stimulus properties of delta-9-tetrahydrocannabinol. Life Sci 38:1581–1589CrossRefPubMedGoogle Scholar
  140. Nava F, Carta G, Colombo G, Gessa GL (2001) Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze. Neuropharmacology 41:392–329CrossRefPubMedGoogle Scholar
  141. Navarro M, Fernandez-Ruiz JJ, de Miguel R, Hernandez ML, Cebeira M, Ramos JA (1993) An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behav Brain Res 57:37–46CrossRefPubMedGoogle Scholar
  142. Navarro M, Chowen J, Rocio A Carrera M, del Arco I, Villanua MA, Martin Y, Roberts AJ, Koob GF, de Fonseca FR (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 9:3397–3402PubMedGoogle Scholar
  143. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, Del Arco I, Villanua MA, Maldonado R, Koob GF, de Fonseca FR (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21:5344–5350PubMedGoogle Scholar
  144. Nowlan R, Cohen S (1977) Tolerance to marijuana: heart rate and subjective "high." Clin Pharmacol Ther 22:550–556Google Scholar
  145. Olds ME, Fobes JL (1981) The central basis of motivation: intracranial self-stimulation studies. Ann Rev Psychol 32:523–574Google Scholar
  146. Olds J, Milner P (1954) Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 47:419–427Google Scholar
  147. Oviedo A, Glowa J, Herkenham M (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 616:293–302Google Scholar
  148. Palmer SL, Thakur GA, Makriyannis A (2002) Cannabinergic ligands. Chem Phys Lipids 121:3–19Google Scholar
  149. Panlilio LV, Goldberg SR, Gilman JP, Jufer R, Cone EJ, Schindler CW (1998) Effects of delivery rate and non-contingent infusion of cocaine on cocaineself-administration in rhesus monkeys. Psychopharmacology 137:253–258PubMedGoogle Scholar
  150. Paton WD (1975) Pharmacology of marijuana. Annu Rev Pharmacol 15:191–220PubMedGoogle Scholar
  151. Perez-Reyes M, White WR, McDonald SA, Hicks RE, Jeffcoat AR, Cook CE (1991) The pharmacologic effects of daily marijuana smoking in humans. Pharmacol Biochem Behav 40:691–694CrossRefPubMedGoogle Scholar
  152. Perio A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G, Soubrie P (1996) Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 7:65–71PubMedGoogle Scholar
  153. Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635–664PubMedGoogle Scholar
  154. Pertwee RG, Stevenson LA, Griffin G (1993) Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212–2 and anandamide. Br J Pharmacol 110:1483–1490PubMedGoogle Scholar
  155. Pickens R, Thompson T, Muchow DC (1973) Cannabis and phencyclidine self-administered by animals. In: Goldfarb L, Hoffmeister F (eds) Psychic dependence [Bayer-Symposium IV]. Springer, Berlin Heidelberg New York, pp 78–86Google Scholar
  156. Piomelli D, Beltramo M, Giuffrida A, Stella N (1998) Endogenous cannabinoid signaling. Neurobiol Dis 5:462–473CrossRefPubMedGoogle Scholar
  157. Piomelli D, Giuffrida A, Calignano A, de Fonseca RF (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21:218–224PubMedGoogle Scholar
  158. Pontieri FE, Tanda G, Di Chiara G (1995) Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the ''shell'' as compared with the ''core'' of the rat nucleus accumbens. Proc Natl Acad Sci USA 92:12304–12308PubMedGoogle Scholar
  159. Pontieri FE, Tanda G, Orzi F, Di Chiara G (1996) Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382:255–257PubMedGoogle Scholar
  160. Pontieri FE, Monnazzi P, Scontrini A, Buttarelli FR, Patacchioli FR (2001a) Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. Eur J Pharmacol 421:R1–R3CrossRefGoogle Scholar
  161. Pontieri FE, Monnazzi P, Scontrini A, Buttarelli FR, Patacchioli FR (2001b) Behavioral sensitization to WIN 55212.2 in rats pretreated with heroin. Brain Res 898:178–180CrossRefPubMedGoogle Scholar
  162. Pope HG, Yurgelun-Todd D (1996) The residual cognitive effects of heavy marijuana use in college students. JAMA 275:521–527CrossRefPubMedGoogle Scholar
  163. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58:909–915PubMedGoogle Scholar
  164. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020–1024CrossRefPubMedGoogle Scholar
  165. Prado-Alcala R, Wise RA (1984) Brain stimulation reward and dopamine terminal fields: I. caudate-putamen, nucleus accumbens and amygdala. Brain Res 297:265–273CrossRefPubMedGoogle Scholar
  166. Richter RM, Pich EM, Koob GF, Weiss F (1995) Sensitization of cocaine-stimulated increase in extracellular levels of corticotropin-releasing factor from the rat amygdala after repeated administration as determined by intracranial microdialysis. Neurosci Lett 187:169–172PubMedGoogle Scholar
  167. Richter RM, Weiss F (1999) In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 32:254–261CrossRefPubMedGoogle Scholar
  168. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur GL (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244PubMedGoogle Scholar
  169. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18:247–291PubMedGoogle Scholar
  170. Robinson TE, Berridge KC (2001) Incentive-sensitization and addiction. Addiction 96:103–114PubMedGoogle Scholar
  171. Romero J, Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA, Fernandez-Ruiz JJ (1997) Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 46:100–108Google Scholar
  172. Romero J, Berrendero F, Manzanares J, Perez A, Corchero J, Fuentes A, Fernandez-Ruiz JJ, Ramos JA (1998) Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta 9-tetrahydrocannabinol. Synapse 30:298–308PubMedGoogle Scholar
  173. Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernandez-Ruiz JJ (2002)The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 95:137–152CrossRefPubMedGoogle Scholar
  174. Rossetti ZL, Melis F, Carboni S, Gessa GL (1991) Marked decrease of extraneuronal dopamine after alcohol withdrawal in rats: reversal by MK-801. Eur J Pharmacol 200:371–372Google Scholar
  175. Rossetti ZL, Hmaidan Y, Gessa GL (1992a) Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 221:227–234PubMedGoogle Scholar
  176. Rossetti ZL, Melis F, Carboni S, Gessa GL (1992b) Dramatic depletion of mesolimbic extracellular dopamine after withdrawal from morphine, alcohol or cocaine: a common neurochemical substrate for drug dependence. Ann NY Acad Sci 654:513–526PubMedGoogle Scholar
  177. Rubino T, Patrini G, Parenti M, Massi P, Parolaro D (1997a) Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Brain Res Mol Brain Res 44:191–197CrossRefPubMedGoogle Scholar
  178. Rubino T, Tizzoni L, Vigano D, Massi P, Parolaro D (1997b) Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport 8:3219–3223PubMedGoogle Scholar
  179. Rubino T, Vigano D, Massi P, Parolaro D (2001) The psychoactive ingredient of marijuana induces behavioural sensitization. Eur J Neurosci 14:884–886CrossRefPubMedGoogle Scholar
  180. Rubio P, de Fonseca RF, Martin-Calderon JL, Del Arco I, Bartolome S, Villanua MA, Navarro M (1998) Maternal exposure to low doses of delta9-tetrahydrocannabinol facilitates morphine-induced place conditioning in adult male offspring. Pharmacol Biochem Behav 61:229–238CrossRefPubMedGoogle Scholar
  181. Sanudo-Pena MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM (1997) Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 223:125–128PubMedGoogle Scholar
  182. Schlichting UU, Goldberg SR, Wuttke W, Hoffmeister F (1971) D-amphetamine self administration by rhesus monkeys with different self administration histories. Excerpta Medica International Congress Series 220:62–69Google Scholar
  183. Smith NT (2002) A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 97:621–632CrossRefPubMedGoogle Scholar
  184. Smith PB, Welch SP, Martin BR (1994) Interactions between Δ9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 268:1381–1387PubMedGoogle Scholar
  185. Takahashi RN, Singer G (1979) Self-administration of Δ9-tetrahydrocannabinol by rats. Pharmacol Biochem Behav 11:737–740PubMedGoogle Scholar
  186. Takahashi RN, Singer G (1980) Effects of body weight levels on cannabis self-administration. Pharmacol Biochem Behav 13:877–881CrossRefPubMedGoogle Scholar
  187. Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common µ1 opioid receptor mechanism. Science 276:2048–2050PubMedGoogle Scholar
  188. Tanda G, Loddo P, Di Chiara G (1999) Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 376:23–26Google Scholar
  189. Tanda G, Munzar P, Goldberg SR (2000) Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nature Neurosci 3:1073–1074CrossRefPubMedGoogle Scholar
  190. Thorat SN, Bhargava HN (1994) Evidence for a bidirectional cross-tolerance between morphine and Δ9-tetrahydrocannabinol in mice. Eur J Pharmacol 260:5–13CrossRefPubMedGoogle Scholar
  191. Tsou K, Patrick SL, Walker JM (1995) Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280:R13–R15CrossRefPubMedGoogle Scholar
  192. Tzschentke TM (1998) Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56:613–672PubMedGoogle Scholar
  193. Valjent E, Maldonado R (2000) A behavioural model to reveal place preference to Δ9-tetrahydrocannabinol in mice. Psychopharmacology 147:436–438Google Scholar
  194. Valverde O, Maldonado R, Valjent E, Zimmer AM, Zimmer A (2000) Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 20:9284–9289Google Scholar
  195. Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP (2001) Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 13:1816–1824PubMedGoogle Scholar
  196. Van Ree JM, Slangen JL, de Wied D (1978) Intravenous self-administration of drugs in rats. J Pharmacol Exp Ther 204:547–557Google Scholar
  197. Vela G, Ruiz-Gayo M, Fuentes JA (1995) Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34:665–668Google Scholar
  198. Vela G, Martin S, Garcia-Gil L, Crespo JA, Ruiz-Gayo M, Javier Fernandez-Ruiz J, Garcia-Lecumberri C, Pelaprat D, Fuentes JA, Ramos JA, Ambrosio E (1998) Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mμ opioid receptors in adult offspring female rats. Brain Res 807:101–109Google Scholar
  199. Wachtel SR, de Wit H (2000) Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans. Drug Alcohol Depend 59:251–260CrossRefPubMedGoogle Scholar
  200. Wakasa Y, Takada K, Yanagita T (1995) Reinforcing effect as a function of infusion speed in intravenous self-administration of nicotine in rhesus monkeys. Nihon Shinkei Seishin Yakurigaku Zasshi 15:53–59PubMedGoogle Scholar
  201. Weisbeck GA, Schuckit MA, Kalmijn JA, Tipp JE, Bucholz KK, Smith TL (1996) An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 91:1469–1478CrossRefPubMedGoogle Scholar
  202. Walker JM, Krey JF, Chu CJ, Huang SM (2002) Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 121:159–172Google Scholar
  203. Welch SP (1997) Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Depend 45:39–45CrossRefPubMedGoogle Scholar
  204. Wiley JL (1999) Cannabis: discrimination of "internal bliss"? Pharmacol Biochem Behav 64:257–260Google Scholar
  205. Wiley JL, Martin BR (1999) Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination. Pharmacol Biochem Behav 64:519–522CrossRefPubMedGoogle Scholar
  206. Wiley JL, Barrett RL, Balster RL, Martin BR (1993a) Tolerance to the discriminative stimulus effects of delta(9)-tetrahydrocannabinol. Behav Pharmacol 4:581–585PubMedGoogle Scholar
  207. Wiley JL, Barrett RL, Britt DT, Balster RL, Martin BR (1993b) Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9–11-tetrahydrocannabinol in rats and rhesus monkeys. Neuropharmacology 32:359–365CrossRefPubMedGoogle Scholar
  208. Wiley JL, Balster RL, Martin BR (1995a) Discriminative stimulus effects of anandamide in rats. Eur J Pharmacol 276:49–54PubMedGoogle Scholar
  209. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR (1995b) Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34:669–676Google Scholar
  210. Wiley JL, Huffman JW, Balster RL, Martin BR (1995c) Pharmacological specificity of the discriminative stimulus effects of Δ9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend 40:81–86CrossRefPubMedGoogle Scholar
  211. Wiley JL, Golden KM, Ryan WJ, Balster RL, Razdan RK, Martin BR (1997) Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. Pharmacol Biochem Behav 58:1139–1143PubMedGoogle Scholar
  212. Wiley JL, Ryan WJ, Razdan RK, Martin BR (1998) Evaluation of cannabimimetic effects of structural analogs of anandamide in rats. Eur J Pharmacol 355:113–118PubMedGoogle Scholar
  213. Wise RA (1987) The role of reward pathways in the development of drug dependence. Pharmacol Ther 35:227–263Google Scholar
  214. Wise RA (1996) Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19:319–340PubMedGoogle Scholar
  215. Woods JH, Young AM, Herling S (1982) Classification of narcotics on the basis of their reinforcing, discriminative, and antagonist effects in rhesus monkeys. Federal Proceedings 41:221–227Google Scholar
  216. Wu X, French ED (2000) Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology 39:391–398CrossRefPubMedGoogle Scholar
  217. Yokel RA (1987) Intravenous self-administration: response rates, the effects of pharmacological challenges, and drug preference. In: Bozarth MA (ed) Methods of assessing the reinforcing properties of abused drugs. Springer, Berlin Heidelberg New York, pp 1–33Google Scholar
  218. Young AM, Herling S (1986) Drugs as reinforcers: studies in laboratory animals. In: Goldberg SR, Stolerman IP (eds) Behavioral analysis of drug dependence. Academic Press, Orlando, FL, pp 9–67Google Scholar
  219. Young AM, Herling S, Woods JH (1981a) History of drug exposure as a determinant of drug self administration. In: Thompson T, Johanson CE (eds) Behavioral pharmacology of human drug dependence. NIDA research monograph, Washington, DC, 37:75–89Google Scholar
  220. Young AM, Herling S, Winger GD, Woods JH (1981b) Comparison of discriminative and reinforcing effects of ketamine and related compounds in the rhesus monkey. In: Harris LS (ed) Problems of drug dependence. NIDA research monograph, Washington, DC, 34:173–179Google Scholar
  221. Zhuang S, Kittler J, Grigorenko EV, Kirby MT, Sim LJ, Hampson RE, Childers SR, Deadwyler SA (1998) Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res Mol Brain Res 62:141–149CrossRefPubMedGoogle Scholar
  222. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780–5785PubMedGoogle Scholar
  223. Zimmer A, Valjent E, Konig M, Zimmer AM, Robledo P, Hahn H, Valverde O, Maldonado R (2001) Absence of Δ-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J Neurosci 21:9499–9505PubMedGoogle Scholar
  224. Zygmunt PM, Andersson DA, Hogestatt ED (2002) Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 22:4720–4727PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Psychobiology Section, Medications Discovery Research Branch, National Institute on Drug Abuse, National Institutes of Health, Intramural Research ProgramDepartment of Health and Human ServicesBaltimoreUSA
  2. 2.Preclinical Pharmacology Section, Behavioral Neurosciences Branch, National Institute on Drug Abuse, National Institutes of Health, Intramural Research ProgramDepartment of Health and Human ServicesBaltimoreUSA

Personalised recommendations